Press release
Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia
TruSight™ Oncology 500 ctDNA panel to be used across a number of Asian countries to develop personalized cancer treatments for Nasopharyngeal Carcinoma SAN
About this update from Illumina, Inc.
[{"type":"text","content":"TruSight™ Oncology 500 ctDNA panel to be used across a number of Asian countries to develop personalized cancer treatments for Nasopharyngeal Carcinoma\n\n\nSAN DIEGO, Jan. 24, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and the National Cancer Center Japan have announced an international joint research project that will use Illumina's high-throughput DNA sequencing to analyse the blood-based genomic profile and clinical information of patients living with Nasopharyngeal Carcinoma. The study will be known as a part of the Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing (A-TRAIN). \n\n \n \n \n \n \n \n\n \nOne of the main research areas of the project is nasopharyngeal carcinoma, a rare tumor of the head and neck which originates in the nasopharynx and has a higher incidence rate in Asian countries. More than 80 percent of new cases occur in Asia, with Southeast Asian countries accounting for 67 percent of the global burden of all cancer. Nasopharyngeal cancer ranked ninth among incident cancers and eighth among cancer deaths in Southeast Asia.\n\"We are immensely proud to contribute to this international collaboration and prospective study,\" said Gretchen Weightman, Head of Global Commercial Strategy and General Manager of Asia Pacific and Japan at Illumina. \"Through our joint efforts, we will fuel initiatives that improve health outcomes for people living with nasopharynx cancer and progress the development of personalized treatment, especially those in the Asian community where this carcinoma is most prevalent.\"\n\"As nasopharyngeal carcinoma occurs more frequently in Asia and is more difficult to treat, there is a strong need to develop new treatments,\" said Dr. Kan Yonemori, Principal Investigator at A-TRAIN. \"A comprehensive genome profiling panel is a powerful tool to help solve this problem by using blood for genetic analysis. We are grateful for Illumina's support in enabling this important research in numerous Asian countries.\"\nThe A-TRAIN study led by the National Cancer Center Hospital Japan is an international joint research project in a number of Asian countries to develop novel treatments based on genomic abnormalities for cancers that are common in Asia. The overall project includes research involving patients with cervical cancer, ovarian cancer, ovarian clear cell carcinoma...